BridgeBio Pharma Inc.
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update
Summary
BridgeBio Pharma, Inc. reported its third quarter 2024 financial results and provided an update on its operations. The company's pipeline is progressing, with three Phase 3 readouts expected in 2025. Highlights include positive data from the ATTRibute-CM study for acoramidis, a near-complete transthyretin stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM). The company also anticipates a milestone payment of $500 million upon FDA approval of acoramidis. As of September 30, 2024, BridgeBio had $406 million in cash, cash equivalents, and short-term restricted cash.
Profitelligence Alerts
Get alerts for BBIO
Be first to know when BridgeBio Pharma Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About BridgeBio Pharma Inc.
BridgeBio Pharma Inc. is a cutting-edge biotechnology company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases. The company's primary purpose is to bridge the gap in medical research and bring breakthrough therapies to those with rare and often overlooked genetic disorders. By utilizing a targeted approach, BridgeBio Pharma Inc. works across multiple sectors including dermatology, oncology, cardiology, neurology, and endocrinology. The company partners with academic institutions, research organizations, and industry leaders to harness the latest scientific advancements in genomics and biotechnology. Established with a mission to translate genetic research into real-world medical solutions, BridgeBio Pharma Inc. plays a significant role in the biopharmaceutical market. It is heavily involved in the early and late stages of drug development, positioning itself as a key player in the quest to address unmet medical needs. This focus on genetic-centric therapies underlines its importance in the rapidly evolving landscape of biotechnology and personalized medicine.
Official SEC Documents
Advertisement